2-溴-6-氯吡啶-3-氨基甲酸叔丁酯 | 1227958-32-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-溴-6-氯吡啶-3-氨基甲酸叔丁酯
• 中文别名: N-(2-溴-6-氯-3-吡啶基)氨基甲酸叔丁酯
• 英文名称: tert-butyl (2-bromo-6-chloropyridin-3-yl)carbamate
• 英文别名: tert-Butyl (2-bromo-6-chloropyridin-3-yl)carbamate；tert-butyl N-(2-bromo-6-chloropyridin-3-yl)carbamate
• CAS: 1227958-32-8
• 化学式: C₁₀H₁₂BrClN₂O₂
• 分子量: 307.574
• InChiKey: ZFFFXKCZHWHRET-UHFFFAOYSA-N

物化性质

• 沸点：
  325.5±42.0 °C(Predicted)
• 密度：
  1.539±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  51.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-溴-6-氯吡啶-3-氨基甲酸叔丁酯 在 1,3-二甲基-2-咪唑啉酮 、 甲基锂 、 caesium carbonate 、 肼 作用下， 以 四氢呋喃 、 二乙氧基甲烷 、 水 、 乙腈 为溶剂， -55.0~155.0 ℃ 、344.75 kPa 条件下， 反应 12.75h， 生成 6-hydrazinyl-3-phenyl-1,5-naphthyridin-2(1H)-one
  参考文献：
  名称：

  Convergent, Kilogram Scale Synthesis of an Akt Kinase Inhibitor

  摘要：

  The development of a convergent, chromatography-free synthesis of an allosteric Akt kinase inhibitor is described. The route comprised 17 total steps and was used to produce kilogram quantities of the target molecule. A key early transformation, for which both batch and flow protocols were developed, was formylation of a dianion derived by deprotonation and subsequent lithium-halogen exchange from a 2-bromo-3-aminopyridine precursor. Improved reaction yield and practicality were achieved in the continuous processing mode. Further significant process developments included the safe execution of a high temperature and pressure hydrazine displacement, separation of substituted cyclobutane diastereomers by means of chemoselective ester hydrolysis, and a late-stage Suzuki fragment coupling under mild conditions.

  DOI：

  10.1021/op300031r
• 作为产物：
  描述：

  2-氯-5-氨基吡啶 在 N-溴代丁二酰亚胺(NBS) 、 sodium hexamethyldisilazane 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.5h， 生成 2-溴-6-氯吡啶-3-氨基甲酸叔丁酯
  参考文献：
  名称：

  Convergent, Kilogram Scale Synthesis of an Akt Kinase Inhibitor

  摘要：

  The development of a convergent, chromatography-free synthesis of an allosteric Akt kinase inhibitor is described. The route comprised 17 total steps and was used to produce kilogram quantities of the target molecule. A key early transformation, for which both batch and flow protocols were developed, was formylation of a dianion derived by deprotonation and subsequent lithium-halogen exchange from a 2-bromo-3-aminopyridine precursor. Improved reaction yield and practicality were achieved in the continuous processing mode. Further significant process developments included the safe execution of a high temperature and pressure hydrazine displacement, separation of substituted cyclobutane diastereomers by means of chemoselective ester hydrolysis, and a late-stage Suzuki fragment coupling under mild conditions.

  DOI：

  10.1021/op300031r

文献信息

• [EN] SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE<br/>[FR] INHIBITEURS À PETITE MOLÉCULE DE KINASE INDUISANT NF-KB
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2020239999A1

  公开（公告）日：2020-12-03

  The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.

  本发明涉及抑制NIK的化合物，以及包含这些化合物的药物组合物和使用方法。这些化合物和药物组合物预期能用于预防或治疗癌症（如包括白血病、淋巴瘤和多发性骨髓瘤的B细胞恶性肿瘤）、炎症性疾病、自身免疫疾病、免疫皮肤病学疾病（如掌跖脓疱病和化脓性汗腺炎）以及代谢紊乱疾病（如肥胖和糖尿病）。
• [EN] ANTIVIRAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIVIRAUX
  申请人：ALIOS BIOPHARMA INC

  公开号：WO2015026792A1

  公开（公告）日：2015-02-26

  Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).

  本文披露了新的抗病毒化合物，以及包括一种或多种抗病毒化合物的药物组合物，以及合成这些化合物的方法。本文还披露了使用一种或多种小分子化合物改善和/或治疗副粘病毒病毒感染的方法。副粘病毒感染的例子包括由人类呼吸道合胞病毒（RSV）引起的感染。
• HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20210332045A1

  公开（公告）日：2021-10-28

  Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.

  提供了一种化合物，可以抑制MALT1，并且预计作为预防或治疗癌症等疾病的药物是有用的。化合物由式(I)表示[其中每个符号如描述中所定义]，其盐，或其共晶体，水合物或溶剂化合物。
• ANTIVIRAL COMPOUNDS
  申请人：Alios BioPharma, Inc.

  公开号：US20150065504A1

  公开（公告）日：2015-03-05

  Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).

  本文披露了新的抗病毒化合物，以及包括一种或多种抗病毒化合物的制药组合物和合成方法。本文还披露了使用一种或多种小分子化合物改善和/或治疗副黏液病毒病毒感染的方法。副黏液病毒感染的例子包括由人类呼吸道合胞病毒(RSV)引起的感染。
• Heterocyclic compound
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US11230545B2

  公开（公告）日：2022-01-25

  Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.

  本发明提供了一种化合物，该化合物具有抑制 MALT1 的效果，有望用作癌症等的预防或治疗药物。一种由式（I）[其中各符号如描述中所定义]代表的化合物、其盐或其共晶体、水合物或溶液。